Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Receivables (2016 - 2019)

Theravance Biopharma (TBPH) has disclosed Change in Receivables for 7 consecutive years, with -$86000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Change in Receivables rose 96.42% to -$86000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was -$620000.0, a 62.03% increase, with the full-year FY2019 number at -$620000.0, up 62.03% from a year prior.
  • Change in Receivables was -$86000.0 for Q4 2019 at Theravance Biopharma, up from -$145000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.5 million in Q2 2018 to a low of -$2.4 million in Q4 2018.
  • A 5-year average of -$14450.0 and a median of $45500.0 in 2015 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: tumbled 4368.18% in 2016, then soared 1192.92% in 2018.
  • Theravance Biopharma's Change in Receivables stood at $1.1 million in 2015, then crashed by 119.93% to -$227000.0 in 2016, then skyrocketed by 398.24% to $677000.0 in 2017, then plummeted by 455.1% to -$2.4 million in 2018, then skyrocketed by 96.42% to -$86000.0 in 2019.
  • Per Business Quant, the three most recent readings for TBPH's Change in Receivables are -$86000.0 (Q4 2019), -$145000.0 (Q3 2019), and $118000.0 (Q2 2019).